Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease cystic fibrosis
Symptom |lung infection
Sentences 71
PubMedID- 25443661 Nocardia farcinica lung infection in a patient with cystic fibrosis and a lung transplant.
PubMedID- 25147668 One of the most medically important biofilm-forming species is pseudomonas aeruginosa, which is commonly associated with lung infections in patients with cystic fibrosis.
PubMedID- 22679547 Patients who have end stage lung diseases such as cystic fibrosis, bronchiectasia along with secondary lung infections need lung transplantation to prolong their life.
PubMedID- 25036925 Chronic bacterial lung infections associated with non-cystic fibrosis bronchiectasis represent a substantial and growing health-care burden.
PubMedID- 20934258 Pseudomonas aeruginosa is the major pathogen of chronic lung infections in individuals with cystic fibrosis (cf).
PubMedID- 25705428 In the last decade, many studies published the use of colistin in the treatment of lung infection in patients without cystic fibrosis, with conflicting results.
PubMedID- 23486248 Cenocepacia is known for its ability to cause lung infections in people with cystic fibrosis and it possesses a large 8 mb multireplicon genome encoding a wide array of pathogenicity and fitness genes.
PubMedID- 23281188 In chronic lung infections of people with cystic fibrosis, p. aeruginosa inhabits viscous, adhesive mucus, which likely retards the diffusion of secreted molecules.
PubMedID- 25861288 During the last 2 decades, colistin was mainly restricted to treat acute exacerbations of lung infections in patients with cystic fibrosis .
PubMedID- 23235684 Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.
PubMedID- 20211000 Nocardia farcinica lung infection in a patient with cystic fibrosis: a case report.
PubMedID- 23984384 However, the most serious medical problem caused by p. aeruginosa is lung infection associated with cystic fibrosis 3.
PubMedID- 25470304 Objectives: the objective of our review was to compare antibiotic treatment to no antibiotic treatment, or to compare different combinations of antibiotic treatment, for nontuberculous mycobacteria lung infections in people with cystic fibrosis.
PubMedID- 23642644 During chronic lung infections of cystic fibrosis (cf) patients pseudomonas aeruginosa adapts by accumulating mutations associated with phenotypic adaptations, leading to populations of p. aeruginosa composed of multiple clones with differing antimicrobial susceptibility profiles .
PubMedID- 20951086 Murine models of acute and chronic lung infection with cystic fibrosis pathogens.
PubMedID- 24454693 P. aeruginosa is also widely studied as an opportunistic pathogen of plants, animals and humans and in particular, as a pathogen causing persistent and frequently fatal lung infections in patients with cystic fibrosis (cf) 8.
PubMedID- 21926193 Although only poorly documented, it can be assumed that intensive antibiotic treatments of chronic lung infections in patients with cystic fibrosis (cf) also affect the diversity and metabolic functioning of the gastrointestinal microbiota and potentially lead to a state of dysbiosis.
PubMedID- 20644645 Clinical scvs are usually isolated from patients suffering from chronic infections (e.g., from lung infections due to cystic fibrosis or from osteomyelitis) .
PubMedID- 21178134 Tobramycin inhalation solution usp (tobi), a therapy developed to treat lung infections associated with cystic fibrosis (cf), was presented as a demonstration case for collaborative pharmaceutical development at a clinical and translational science awards industry forum on "promoting efficient and effective collaborations among academia, government, and industry" held in february 2010.
PubMedID- 23481089 However whether and how it can be used for the treatment of bacterial lung infections in patients with cystic fibrosis is unclear.
PubMedID- 20837573 Objectives: to test the presumption that pseudomonas aeruginosa isolates responsible for initial lung infection in individuals with cystic fibrosis (cf) are invariably susceptible to antipseudomonal agents.

Page: 1 2